Complex chemical polymers are currently being developed by scientists at Stanford University to protect and support the proliferation of stem cells during spinal cord transplantation procedures. The gels are designed to provide padding for the cells during injection, while also varying in viscosity and the biochemical signals contained within to offer stem cells an optimal environment for differentiation. Continue reading
In a recently published study by the University of Minnesota, researchers are utilizing skeletal muscle stem cells in an animal model designed to study the muscle-degenerative protein DUX4 found in patients with facioscapulohumeral muscular dystrophy [FSHD]. The team was able to harvest the muscle stem cells from one mouse with FSHD and transplant them into a recipient mouse, allowing the recipient to regenerate new muscle as long as DUX4 was not activated. Continue reading
Researchers at the University of California, San Diego are set to begin clinical trials to test the safety and effectiveness of a neural stem cell transplant designed to treat spinal cord injuries. In an animal model, the stem cells were able to regenerate the nerves across the site of injury, resulting in the restoration of mobility in the legs. Continue reading
A recently published study by University of Illinois Kinesiology and Community Health Professor Marni Boppart has identified mesenchymal stem cells [MSCs] as a tool for rejuvenating muscle to prevent age-related injuries and disabilities. In addition to their ability to differentiate into other cell types, MSCs were found to secrete growth factors that stimulate the activation of the multiple cell types comprising skeletal muscle, including muscle precursor cells and satellite cells, which lose function with age. Continue reading
Recent research from the University of Colorado Boulder has identified two stem cell signaling pathways that are directly related to the age-related degeneration of muscle tissue and the onset of a variety of muscle-wasting diseases, such as muscular dystrophy and sarcopenia. By altering these pathways, the investigators were able to enhance muscle stem cell renewal and improve muscle regeneration. Continue reading
In a recent Phase II clinical study, researchers report that mesenchymal stem cells were successful in relieving chronic lower back pain. The scientists injected MSCs directly into the degenerating vertebral disks of patients suffering from lower back pain, resulting in an overall reduction in the mean pain score, improved function for at least 12 months, and a reduced need for further surgical and non-surgical treatment interventions.
Of the 6 million Americans suffering from debilitating back pain today, 3.5 million are affected by degenerative invertebral disk disease. The results of this clinical trial show that, instead of addressing the symptoms, mesenchymal stem cells are able to treat the source of the pain for long lasting relief. According to lead researcher, Dr. Tory McJunkin, M.D, “This study shows we are progressing toward major advances in pain medicine,”
Mesenchymal stem cells have the unique capacity to regenerate a multitude of different types of tissues – such as neurons, insulin producing pancreatic beta cells, bone, cartilage, and cardiomyocites amongst them. This Phase II study is just one example of the utility of stem cells in successfully treating conditions previously thought to be untreatable or treatable only through invasive options. To learn how to bank your own valuable stem cells to insure access to emerging regenerative therapies, visit www.stemsave.com or call 877-783-6728 877-StemSave) today.
A medical team from the University of Calgary is now recruiting candidates to participate in the phase one clinical trial for a new stem cell therapy that aims to treat spinal cord injuries. The researchers plan to inject stem cells into the spinal cord two sites above and two sites below the point of injury to recreate lost or damaged tissue. Continue reading
As the most common genetic neurological disease contributing to infant mortality, researchers have been exploring the utility of autologous stem cell therapies (or therapies that use a patient’s own stem cells) in treating Spinal muscular atrophy (SMA).